Overbrook Management Corp Purchases New Shares in HealthEquity, Inc. (NASDAQ:HQY)

Overbrook Management Corp acquired a new position in HealthEquity, Inc. (NASDAQ:HQY) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 142,501 shares of the company’s stock, valued at approximately $12,284,000. HealthEquity makes up approximately 3.1% of Overbrook Management Corp’s holdings, making the stock its 13th largest position.

A number of other large investors have also recently made changes to their positions in the business. Rise Advisors LLC purchased a new stake in shares of HealthEquity in the first quarter valued at $28,000. Cape Investment Advisory Inc. purchased a new stake in HealthEquity in the 4th quarter worth about $27,000. YHB Investment Advisors Inc. bought a new stake in HealthEquity in the first quarter worth about $40,000. Fidelis Capital Partners LLC bought a new position in shares of HealthEquity during the first quarter valued at approximately $42,000. Finally, GAMMA Investing LLC raised its holdings in shares of HealthEquity by 114.8% in the second quarter. GAMMA Investing LLC now owns 595 shares of the company’s stock worth $51,000 after buying an additional 318 shares during the period. 99.55% of the stock is currently owned by institutional investors.

Insider Transactions at HealthEquity

In other HealthEquity news, Vice Chairman Stephen Neeleman sold 35,000 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $79.86, for a total value of $2,795,100.00. Following the completion of the sale, the insider now owns 89,769 shares of the company’s stock, valued at $7,168,952.34. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, Vice Chairman Stephen Neeleman sold 35,000 shares of the company’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $79.86, for a total value of $2,795,100.00. Following the transaction, the insider now directly owns 89,769 shares of the company’s stock, valued at approximately $7,168,952.34. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Jon Kessler sold 32,326 shares of HealthEquity stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $82.83, for a total value of $2,677,562.58. Following the sale, the chief executive officer now directly owns 232,176 shares of the company’s stock, valued at approximately $19,231,138.08. The disclosure for this sale can be found here. Insiders sold 77,511 shares of company stock valued at $6,314,446 in the last quarter. 2.20% of the stock is currently owned by corporate insiders.

HealthEquity Stock Up 2.0 %

NASDAQ HQY traded up $1.47 during midday trading on Friday, hitting $76.62. 378,723 shares of the company traded hands, compared to its average volume of 621,563. HealthEquity, Inc. has a 52 week low of $61.81 and a 52 week high of $88.26. The company’s 50-day simple moving average is $78.18 and its 200-day simple moving average is $79.80. The company has a market cap of $6.67 billion, a PE ratio of 83.28, a price-to-earnings-growth ratio of 1.31 and a beta of 0.57. The company has a debt-to-equity ratio of 0.44, a current ratio of 4.39 and a quick ratio of 4.39.

HealthEquity (NASDAQ:HQY) last posted its earnings results on Monday, June 3rd. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.08. The company had revenue of $287.60 million for the quarter, compared to analyst estimates of $278.78 million. HealthEquity had a return on equity of 7.77% and a net margin of 7.71%. As a group, equities research analysts forecast that HealthEquity, Inc. will post 2.12 earnings per share for the current year.

Wall Street Analyst Weigh In

HQY has been the subject of a number of recent analyst reports. Bank of America restated a “buy” rating and set a $105.00 price objective on shares of HealthEquity in a report on Wednesday, July 3rd. Robert W. Baird upped their price target on shares of HealthEquity from $98.00 to $104.00 and gave the stock an “outperform” rating in a report on Tuesday, June 4th. Raymond James lifted their price objective on shares of HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Friday, June 7th. JMP Securities upped their target price on shares of HealthEquity from $101.00 to $105.00 and gave the stock a “market outperform” rating in a research note on Tuesday, June 4th. Finally, Wells Fargo & Company raised their target price on shares of HealthEquity from $107.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, June 20th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $101.67.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.